Desert Stream

Desert Stream is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation oncolytic virus therapies. The company's core technology centers on a proprietary herpes simplex virus type 1 (HSV-1) platform designed to selectively infect and lyse cancer cells while stimulating a systemic anti-tumor immune response. Their lead programs target difficult-to-treat solid tumors, including glioblastoma and gastrointestinal cancers. By engineering viruses to carry therapeutic payloads such as cytokines or immune checkpoint inhibitors, Desert Stream aims to overcome the immunosuppressive tumor microenvironment. The company is currently advancing several candidates through early-phase clinical trials in China and seeking international collaborations.